Key Highlights

● Aquestive's board appointed Richard J. Daly as an independent Class I director, effective October 14, 2026.

● The board is increasing directorships from seven to eight, and seven of the eight directors will be independent.

● Mr. Daly will receive 57,000 stock options under the 2018 Equity Incentive Plan, vesting in annual one-third increments.

● Mr. Daly is President of Global Rare Disease at Angelini Pharma S.p.A. and has more than 30 years of experience.

Aquestive Therapeutics, Inc. (NASDAQ:AQST) announced in a Form 8-K filed on September 29, 2026 that its board of directors has appointed Richard J. Daly as an independent Class I director, effective October 14, 2026. To make room, the board is increasing the number of directorships from seven to eight, effective the same day. The filing also discloses that Mr. Daly will receive a grant of 57,000 stock options.

The Appointment and Compensation

The 8-K reports the appointment under Item 5.02 and attaches a press release as Exhibit 99.1. According to the filing, Mr. Daly's term as a Class I director will run until the company's 2028 Annual Meeting of Stockholders, or until his earlier death, resignation or removal. After his election the board will have eight directors, seven of whom are independent. The filing states that the board determined Mr. Daly "has no material relationship with the Company that would affect his independence" and that he qualifies as independent under Nasdaq listing rules. It does not assign him to any committee at this time.

The filing also states that Mr. Daly has no family relationships with any director or officer of the company, no transactions requiring disclosure, and was not selected under any arrangement with another party.

Mr. Daly will take part in the company's non-employee director compensation program, which the filing says is described in the company's proxy statement dated April 24, 2026. As part of that program he will receive 57,000 stock options under the company's 2018 Equity Incentive Plan. The exercise price will be the closing market price on The Nasdaq Global Market on the grant date, and the grant date is the second full trading day following the company's next quarterly or annual earnings release. The options vest in annual one-third increments beginning on the first anniversary of the grant date.

Mr. Daly's Background

The 8-K itself does not include a biography, but the press release does. It says Mr. Daly is President of Global Rare Disease at Angelini Pharma S.p.A. Earlier positions listed in the release include President and Chief Executive Officer of Catalyst Pharmaceuticals (NASDAQ:CPRX), Executive Vice President for the Americas at Takeda Pharmaceutical (NYSE:TAK), President of the U.S. diabetes business at AstraZeneca, Chairman and Chief Executive Officer of Neuralstem, Inc., Chief Operating Officer of BeyondSpring Pharmaceuticals and Seed Therapeutics, and President of CARsgen Therapeutics Holdings. The release says he has served on the boards of Catalyst Pharmaceuticals, Opiant Pharmaceuticals, Neuralstem and Synergy Pharmaceuticals, that he has more than 30 years of experience, and that his career began at Abbott Laboratories (NYSE:ABT).

What the Company Said

The press release is titled "Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly." In it, President and Chief Executive Officer Daniel Barber and Chairman Gregory B. Brown, M.D., each comment on Mr. Daly's experience building commercial organizations and supporting product launches. Mr. Daly is quoted as saying: "Anaphylm has the potential to change how patients treat severe allergic reactions, including anaphylaxis."

The release describes Aquestive as a pharmaceutical company developing medicines through innovative science and delivery technologies, headquartered in Warren, New Jersey, with manufacturing in Indiana. It lists Anaphylm (dibutepinephrine) sublingual film for Type I allergic reactions including anaphylaxis, AQST-108 (epinephrine) topical gel for dermatological conditions, and the AdrenaVerse platform of more than 20 epinephrine prodrugs. Those are the company's own descriptions.

Aquestive's Expanded Board and Daly's Option Grant

Mr. Daly's appointment and the enlargement of the board take effect on October 14, 2026. The filing does not assign him to any committee at this time. Because the stock option grant date is tied to the second full trading day after the next quarterly or annual earnings release, the exercise price will not be set until that date.